Steris에 대한 매도 수량은 투자자에게 Steris의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Steris (NYSE:STE) 주식, 공매도 수량 보고

Steris

Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.

What Happened

Upgrades

Markets

Analyst Ratings

Trading Ideas

TSLA

월스트리트의 주요 애널리스트들이 이들 주요 기업들에 대한 전망을 변경했다. 애널리스트의 모든 등급 변경 사항을 완전하게 보려면, 애널리스트 등급 페이지를 참조하세요.

테슬라 분석가가 긍정적으로 전환; 목요일 업그레이드 상위 5종목

Top Performer

News

Movers

EQIX

TEVA

TOST

이들 대형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?테바 파마슈티컬 인더스트리즈(NYSE:TEVA)의 주가는 회사가 엇갈린 1분기 재무 결과를 발표하고 위약과 비교하여 정신분열증이 있는 성인 환자를 대상으로 한 TEV-&#39;749의 3상 솔라리스(SOLARIS) 시험의 효능 부분 결과를 발표했한 후 16.24% 급등했다. 

지난주(5월 5일~5월 11일) 최고의 성과를 낸 10개의 대형주

Steris PLC

Stream Media Corp

Santech Holdings Limited - American Depositary Shares

Santech Holdings Ltd

Scatec ASA

STEER Technologies Inc Ordinary Shares

Steem

STATE ENERGY GRP by STATE ENERGY GROUP INTL ASSETS HLDGS LTD.

Majestic Dragon AeroTech Holdings Ltd

Sintana Energy Inc Warrants (08/03/2024)

Stemtech Corp

Stellar Bancorp Inc

Stem Inc

StepStone Group Inc. - Class A Common Stock

StepStone Group Inc

Step Finance - United States Dollar

STERLING CHECK CORP COM

Lido stETH

Stevia Corp

SRH Total Return Fund, Inc.

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round,</a>&#8220; Jim Cramer recommended selling NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>).
On March 7, NANO Nuclear Energy announced that Florent Heidet, Ph.D. has joined NANO Nuclear as its Chief Technology Officer and Head of <a href="https://www.benzinga.com/quote/NNE/news">Reactor Development</a>.
Cramer said Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) is a &#8220;challenged&#8221; company, and he doesn't really care for it.
RBC Capital analyst Conor McNamara, on March 12, maintained Illumina with an Outperform and lowered the price target from $247 to $128.
When asked about Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>), he said, &#8220;Keep looking but do not press the button.&#8221;
As per the recent news, Archer Aviation and Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), on March 13, collaborated to build the AI foundation for the future of advanced aviation technologies.
The Mad Money host said he has always liked STERIS plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) and recommended buying the stock. &#8220;I think it's just a strong company,&#8221; he added.
Supporting his view, Stephens &amp; Co. analyst Jacob Johnson, on Feb. 6, reiterated Steris with an Overweight rating and maintained a $240 price target.
Cramer said he doesn't know what Sixth Street Specialty Lending, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLX#NYSE">TSLX</a>) really owns, so therefore he can't give his opinion on it.
RBC Capital analyst Kenneth Lee, on Feb. 26, maintained Sixth Street Specialty with an Outperform rating and raised the price target from $23 to $25.
Cramer said he likes Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) very much and recommended to own the stock.
Adding support to his choice, Susquehanna analyst Mehdi Hosseini, on Feb. 20, upgraded Lam Research from Neutral to Positive and raised the price target from $75 to $125.
Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) has been an &#8220;amazing stock for many years,&#8221; Cramer said. He recommended buying the stock.
Supporting his view, UBS analyst David Vogt, on March 5, upgraded Arista Networks from Neutral to Buy and raised the price target from $112 to $115.
Price Action:
<ul>
<li>Illumina shares fell 0.2% to settle at $84.05 on Thursday.</li>
<li>Archer Aviation shares dipped 3.1% to close at $7.25 during the session.</li>
<li>NANO Nuclear Energy shares gained 1.9% to settle at $28.32.</li>
<li>Steris shares fell 0.9% to close at $222.45.</li>
<li>Sixth Street Specialty Lending shares fell 0.9% to close at $21.96 on Thursday.</li>
<li>Lam Research shares fell 1.7% to settle at $75.26.</li>
<li>Arista Networks shares fell 0.1% to close at $80.14 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44298504/top-3-health-care-stocks-youll-regret-missing-this-quarter">Top 3 Health Care Stocks You&#8217;ll Regret Missing This Quarter</a></li>
</ul>
Image: Shutterstock

Media

ACHR

ANET

ILMN

LRCX

PLTR

TSLX

Jim Cramer Says Illumina Is 'Challenged,' Recommends Selling This Industrial Stock

Across the recent three months, 4 analysts have shared their insights on Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Steris and provided 12-month price targets. The average target is $258.75, accompanied by a high estimate of $265.00 and a low estimate of $240.00. This current average has increased by 0.49% from the previous average price target of $257.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1738879437_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Steris is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$265.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Steris. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Steris compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Steris's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Steris's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Steris analyst ratings.</a>
<h2>About Steris</h2>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Steris: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Steris showcased positive performance, achieving a revenue growth rate of 7.33% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Steris's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 11.29%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Steris's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.32%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Steris's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.47%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.36.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 4 Analyst Projections For Steris

JMP Securities analyst Reni Benjamin reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Market Outperform and maintains $265 price target.

Price Target

Reiteration

JMP Securities Reiterates Market Outperform on Steris, Maintains $265 Price Target

Stephens &amp; Co. analyst Jacob Johnson reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Overweight and maintains $240 price target.

Stephens & Co. Reiterates Overweight on Steris, Maintains $240 Price Target

Guidance

STERIS Expects FY25 Adjusted EPS From Cont Ops Of $9.05 - $9.15 (Est $9.06) Vs Prior Expectations Of $9.05 - $9.25, Mainly Driven By Ten Cent Negative Impact From Currency

STERIS Now Expects FY25 As Reported Revenue To Increase Approximately 6% Vs Prior Expectations Of 6.5% To 7.5%

The Q3 earnings report for Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) was released on Wednesday, February 5, 2025 at 04:30 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Steris missed estimated earnings by 0.0%, reporting an EPS of $2.32 versus an estimate of $2.32.
Revenue was down $25.00 million from the same period last year.
<h3>Previous Earnings Records</h3>
Last quarter the company beat on EPS by $0.02 which was followed by a 5.0% drop in the share price the next day.
Here's a look at Steris's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.12</td>
<td>1.98</td>
<td>2.38</td>
<td>2.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.14</td>
<td>2.03</td>
<td>2.58</td>
<td>2.22</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.33B</td>
<td>1.27B</td>
<td>1.43B</td>
<td>1.35B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.33B</td>
<td>1.28B</td>
<td>1.42B</td>
<td>1.40B</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Steris management provided guidance for FY 2025, expecting earnings between $9.05 and $9.15 per share.
To track all earnings releases for Steris <a href="https://www.benzinga.com/quote/STE/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Earnings Summary: Steris Q3

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) reported quarterly earnings of $2.32 per share which met the analyst consensus estimate. This is a 4.5 percent increase over earnings of $2.22 per share from the same period last year. The company reported quarterly sales of $1.37 billion which missed the analyst consensus estimate of $1.38 billion by 0.86 percent. This is a 1.86 percent decrease over sales of $1.40 billion the same period last year.

Earnings Misses

Steris Q3 2025 Adj EPS $2.32, Inline, Sales $1.37B Miss $1.38B Estimate

ALGN

AMSC

AOSL

APPS

ARAY

ARCC

ARES

ASGN

ASYS

AZTA

BARK

BLBD

BSBR

CENT

CENTA

CMRE

CNMD

CNXN

COHR

CPAY

CPRI

CRTO

CSGS

CTSH

CTVA

DGII

DLHC

ENSG

EQNR

EZPW

FORM

GEOS

HOLX

ITUB

KMPR

LFVN

LSAK

LUCK

LVWR

MSTR

MTRX

MUSA

NOTV

NTGR

NVST

NWSA

ODFL

ORLY

PAHC

PFGC

Earnings Scheduled For February 5, 2025

Piper Sandler analyst Jason Bednar maintains Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Overweight and raises the price target from $260 to $265.

Piper Sandler Maintains Overweight on Steris, Raises Price Target to $265

WIIM

STERIS shares are trading higher. The company announced outcomes from the ethylene oxide trial.

The Court declared a mistrial at Plaintiff's request during jury deliberations when dismissal of one of the jurors reduced the jury to fewer than twelve. The Court will schedule the case for re-trial at a later date.
Isomedix intends to continue to vigorously defend against allegations regarding ethylene oxide operations and emissions from the Waukegan, Illinois facility during 2005 to 2008. Deploying its own rigorous best practices, Isomedix has regularly invested in its facilities and has created processes and procedures that meet or exceed the applicable environmental regulatory standards.

Legal

STERIS Announces That Trial Against Isomedix Ended In A Mistrial On Jan. 17; Court To Schedule Case For Re-Trial At Later Date

In the latest quarter, 4 analysts provided ratings for Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $262.5, along with a high estimate of $265.00 and a low estimate of $260.00. Surpassing the previous average price target of $252.50, the current average has increased by 3.96%.
<img src="https://www.benzinga.com/files/images/story/2024/1731952859_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Steris is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$265.00</td>
<td>$255.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Steris. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Steris compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Steris's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Steris's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Steris analyst ratings.</a>
<h2>Get to Know Steris Better</h2>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Understanding the Numbers: Steris's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Steris showcased positive performance, achieving a revenue growth rate of 7.33% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Steris's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 11.29%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Steris's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.32%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.47%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.36, Steris adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Steris Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

JMP Securities analyst David Turkaly reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Market Outperform and maintains $265 price target.

Needham analyst Mike Matson reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Hold.

Needham Reiterates Hold on Steris

Steris shares are trading lower after the company reported worse-than-expected Q2 revenue results

Stephens &amp; Co. analyst Jacob Johnson reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Overweight and maintains $260 price target.

Stephens & Co. Reiterates Overweight on Steris, Maintains $260 Price Target

Steris Reiterates FY25 As Reported Revenue To Increase 6.5-7.5%, Adj EPS From Continuing Operations To Be $9.05 - $9.25, Est $9.16

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) reported quarterly earnings of $2.14 per share which beat the analyst consensus estimate of $2.12 by 0.94 percent. The company reported quarterly sales of $1.33 billion which met the analyst consensus estimate. This is a 1.04 percent decrease over sales of $1.34 billion the same period last year.

Earnings Beats

Steris Q2 2025 Sales $1.328B, Miss $1.33B Estimate

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) reported quarterly earnings of $2.14 per share which beat the analyst consensus estimate of $2.12 by 0.94 percent.

Steris Q2 2025 Adj EPS $2.14 Beats $2.12 Estimate

Dividends

Press Releases

STERIS Raises Dividend to $0.57 per share

STERIS Announces Financial Results for Fiscal 2025 First Quarter

STERIS to Present at the Morgan Stanley Healthcare Conference

STERIS to Host a Conference Call for Fiscal 2025 Second Quarter Financial Results on November 7, 2024

STERIS Declares Dividend of $0.57 per share

STERIS Announces Financial Results for Fiscal 2025 Second Quarter

STERIS Announces Outcome of Ethylene Oxide Trial

STERIS to Host a Conference Call for Fiscal 2025 Third Quarter Financial Results on February 6, 2025

Comments

Steris

매도 수량

Steris (NYSE:STE) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌